Alzheimer's disease (AD), the most common cause of dementia among the elderly, may
either represent the far end of a continuum that begins with age-related memory decline or a …

In the early 1990s, breakthrough discoveries on the genetics of Alzheimer's disease led to
the identification of missense mutations in the amyloid‐β precursor protein gene. Research …

Microglia, the primary immune effector cells in the brain, continually monitor the tissue
parenchyma for pathological alterations and become activated in Alzheimer's disease. Loss …

Alzheimer's disease often results in impaired olfactory perceptual acuity—a potential
biomarker of the disorder. However, the usefulness of olfactory screens to serve as …

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the
impairment of cognitive functions and by beta amyloid (Aβ) plaques in the cerebral cortex …

The hypothesis that amyloid-β (Aβ) peptides are the primary cause of Alzheimer's disease
(AD) remains the best supported theory of AD pathogenesis. Yet, many observations are …

Rifampicin and caffeine are widely used drugs with reported protective effect against
Alzheimer's disease (AD). However, the mechanism underlying this effect is incompletely …

The amyloid precursor protein (APP) is linked to the genetics and pathogenesis of
Alzheimer's disease (AD). It is the parent protein of the β-amyloid (Aβ) peptide, the main …

Development of cerebral amyloid angiopathy (CAA) and A lzheimer's disease (AD) is
associated with failure of elimination of amyloid‐β (Aβ) from the brain along perivascular …

Histochemical analysis of Alzheimer disease (AD) brain tissues indicates that
butyrylcholinesterase (BuChE) is present in β-amyloid (Aβ) plaques. The role of BuChE in …